Published in Hepatitis Weekly, August 16th, 1999
Researchers from Germany's University of Bonn also found that such patients should continue to be screened both during and after therapy ("Autoimmunity induced by interferon-alpha therapy for chronic viral hepatitis," Biomed Pharmacother, June 1999;53(5-6):242-254).
Type 1 interferons, which are mostly alpha-interferons (either as single agents or in combination with antiviral drugs), are currently the standard therapy for chronic viral hepatitis B, B/D, and C. Side-effects are not uncommon and include...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hepatitis Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.